Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Shyhawk Therapeutics

- PMLiVE

Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours

NETs affect approximately seven per 100,000 people in Scotland

- PMLiVE

Ipsen to acquire Memo Therapeutics in deal worth more than €700m

The deal expands the company’s rare disease portfolio

- PMLiVE

Ipsen appoints Michelle Werner as Executive Vice President, President of North America

Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis

- PMLiVE

Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations

Lefranc has served at Ipsen since 2013, most recently as Senior Vice President

- PMLiVE

Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

- PMLiVE

Ipsen’s tumour treatment receives MHRA marketing authorisation

This is the first approval in the UK for previously treated advanced neuroendocrine tumours

- PMLiVE

Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

Treatment options following disease progression have previously been limited for many patients

- PMLiVE

Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

The number of patients newly diagnosed with NETs is believed to be on the rise

- PMLiVE

Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

- PMLiVE

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis

The life-long condition affects approximately 1,900 people in Scotland

- PMLiVE

Over 40 years of Ipsen in the UK: resilience and leadership in the life sciences sector

By Ioana Parsons

- PMLiVE

Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager

The candidate targets a tumour antigen that is highly expressed across several cancer types

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links